Mizuho lowered the firm’s price target on Inspire Medical (INSP) to $70 from $85 and keeps an Outperform rating on the shares. The firm lowered estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $70 from $85 at Stifel
- Inspire Medical price target lowered to $62 from $85 at Evercore ISI
- CMS update ‘directionally positive’ for Inspire Medical, says KeyBanc
- Inspire reimbursement unchanged as CMS confirms APC 5465 mapping, says Stifel
- Inspire Medical price target lowered to $85 from $95 at Stifel